Summary
Midatech Pharma US Inc. (Midatech Pharma) formerly know as Dara BioSciences, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of cancer treatment and supportive care products. The company’s product portfolio includes Soltamox, for the treatment of breast cancer; Bionect, a topical treatment for skin irritation and burns associated with radiation therapy; and Gelclair, a treatment of oral mucositis. Its product pipeline comprises KRN5500, for the treatment of neuropathic pain and DB959, type 2 diabetes and dyslipidemia. The company collaborates with pharmaceutical companies such as Mission Pharmacal to develop and commercialize its product candidates. It distributes its products through retail pharmacies, mail order pharmacies, and long-term care facilities. Midatech Pharma is headquartered in North Carolina, the US.
Midatech Pharma US Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Midatech Pharma US Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Midatech Pharma US Inc., Medical Devices Deals, 2010 to YTD 2016 9
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
DARA BioSciences Enters into Commercialization Agreement with Onxeo 12
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 13
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 14
Licensing Agreements 15
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 15
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 16
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 17
Equity Offering 18
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 18
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 20
Dara BioSciences Announces Private Placement Of Shares For US$6 Million 21
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 23
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 25
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 26
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 28
DARA BioSciences Completes Public Offering Of Units For US$10 Million 30
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 32
DARA BioSciences Completes Public Offering Of Units For US$4.8 Million 34
DARA BioSciences Completes Registered Direct Offering Of Units For US$1.4 Million 36
DARA BioSciences Terminates Underwritten Public Offering Of US$10 Million 38
DARA BioSciences Completes Private Placement Of US$1.72 Million 40
Acquisition 41
Midatech Pharma Acquires Dara BioSciences 41
DARA BioSciences Acquires Oncogenerix 44
Midatech Pharma US Inc. - Key Competitors 45
Key Employees 46
Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Midatech Pharma US Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Midatech Pharma US Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Midatech Pharma US Inc., Medical Devices Deals, 2010 to YTD 2016 9
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
DARA BioSciences Enters into Commercialization Agreement with Onxeo 12
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 13
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 14
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 15
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 16
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 17
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 18
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 20
Dara BioSciences Announces Private Placement Of Shares For US$6 Million 21
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 23
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 25
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 26
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 28
DARA BioSciences Completes Public Offering Of Units For US$10 Million 30
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 32
DARA BioSciences Completes Public Offering Of Units For US$4.8 Million 34
DARA BioSciences Completes Registered Direct Offering Of Units For US$1.4 Million 36
DARA BioSciences Terminates Underwritten Public Offering Of US$10 Million 38
DARA BioSciences Completes Private Placement Of US$1.72 Million 40
Midatech Pharma Acquires Dara BioSciences 41
DARA BioSciences Acquires Oncogenerix 44
Midatech Pharma US Inc., Key Competitors 45
Midatech Pharma US Inc., Key Employees 46
Midatech Pharma US Inc., Subsidiaries 47
List of Figures
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Midatech Pharma US Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Midatech Pharma US Inc., Medical Devices Deals, 2010 to YTD 2016 9
